Scarica l'app Stockscreener
20.43
2.76%
-0.58
Dopo l'orario di chiusura:
20.15
-0.28
-1.37%
Precedente Chiudi:
$21.01
Aprire:
$21.25
Volume 24 ore:
1.05M
Relative Volume:
1.24
Capitalizzazione di mercato:
$1.40B
Reddito:
-
Utile/perdita netta:
$-131.11M
Rapporto P/E:
-9.3953
EPS:
-2.1745
Flusso di cassa netto:
$-102.47M
1 W Prestazione:
-6.11%
1M Prestazione:
-18.70%
6M Prestazione:
-48.42%
1 anno Prestazione:
+52.58%
Intervallo 1D:
$20.17
$21.39
Intervallo di 1 settimana:
$20.17
$22.62
Portata 52W:
$12.98
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
20.43 | 1.50B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Guggenheim | Buy |
| 2026-04-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
Raymond James Updates Healthcare Top Picks for October - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - PR Newswire
Will Phase 2 Safety Concerns Change Tyra Biosciences Stock Narrative - Simply Wall Street
Bronstein, Gewirtz & Grossman, LLC Is Investigating Tyra Bioscien - The National Law Review
Tyra Biosciences, Inc. (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bank of America Corp DE Purchases 349,732 Shares of Tyra Biosciences, Inc. $TYRA - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Tyra Biosciences, Inc. (TYRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89 - MarketBeat
ETFs Investing in Tyra Bioscience, Inc Stocks - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tyra Biosciences, Inc. (TYRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Paradigm Biocapital Advisors LP Adds 1,644,846 Shares of Tyra Bi - GuruFocus
Equities Analysts Set Expectations for TYRA FY2026 Earnings - MarketBeat
Tyra Biosciences (TYRA) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
(TYRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Tyra Biosciences, Inc. (TYRA) Investigation: Bronstein, Gewirtz - The National Law Review
Tyra Biosciences (NASDAQ:TYRA) Trading Down 6.7% on Analyst Downgrade - MarketBeat
Bladder Cancer Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight - Barchart.com
Oppenheimer reiterates Outperform rating on Tyra Biosciences, $40 price target - TradingView
Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating - marketscreener.com
H.C. Wainwright cuts Tyra Biosciences price target to $29 on dilution - Investing.com
Tyra Biosciences (NASDAQ:TYRA) Price Target Lowered to $29.00 at HC Wainwright - MarketBeat
HC Wainwright & Co. maintains Buy rating on Tyra Biosciences, $29 price target - TradingView
Biotech fund group reports stake in Tyra Biosciences (NASDAQ: TYRA) — here’s how much of the company it holds - Stock Titan
Tyra Biosciences (Nasdaq:TYRA)Stock Analysis - Simply Wall Street
Press Releases about Tyra Biosciences, Inc.Common Stock (Nasdaq:TYRA) - FinancialContent
Fuhrman Alan Acquires Additional 951 Shares, Holding 37,115 Tyra Biosciences Stocks Post-Award - Kalkine Media
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Unveiling a 97.71% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Tyra Biosciences (NASDAQ: TYRA) CEO lifts stake to 1,438,495 shares - Stock Titan
Stock grant lifts Tyra Biosciences (NASDAQ: TYRA) finance VP stake to 11,258 shares - Stock Titan
CFO adds shares in Tyra Biosciences (TYRA) via plan - Stock Titan
Tyra Biosciences (TYRA) investor uses capped warrants to reach 19.99% stake - Stock Titan
RA Capital buys $0.001-share warrants in Tyra Biosciences (TYRA) - Stock Titan
Investor group reports over 5% stake in Tyra Biosciences (TYRA) - Stock Titan
Tyra Biosciences faces securities fraud probe a... - Pluang
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? - Yahoo Finance
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets - Yahoo Finance
Tyra Biosciences Announces $400 Million Public Offering of Common Stock and Pre-Funded Warrants - Kalkine Media
Squarepoint Ops LLC Purchases 43,311 Shares of Tyra Biosciences, Inc. $TYRA - MarketBeat
Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Tyra Bioscience Shares Rise After Pricing $400 Million Offering - marketscreener.com
Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday - Benzinga
Tyra Biosciences prices $400 million stock offering By Investing.com - Investing.com Nigeria
Tyra Biosciences Insider Verjee Rehan Acquires 972 Shares at $20.58 Each (NASDAQ: TYRA) - Kalkine Media
Tyra Bioscience Prices $400 Million Offering of Shares and Warrants - marketscreener.com
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - TradingView
Cantor Fitzgerald reiterates Tyra Biosciences stock rating By Investing.com - Investing.com Canada
Tyra Biosciences (TYRA) director adds shares in open-market buy - Stock Titan
Tyra Biosciences (NASDAQ:TYRA) Director Buys $20,003.76 in Stock - MarketBeat
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):